Ascendis Pharma AS (ASND) — Cash Flow-to-Debt Ratio
Ascendis Pharma AS (ASND) has a Cash Flow-to-Debt Ratio of -0.01x as of March 2026, meaning its operating cash flow of $-7.85 Million could theoretically repay 0% of its total liabilities ($1.52 Billion) in one year. See Ascendis Pharma AS (ASND) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ascendis Pharma AS Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Ascendis Pharma AS across 14 annual periods. Also explore how fast is Ascendis Pharma AS growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Ascendis Pharma AS (2012–2025)
Year-by-year debt coverage analysis for Ascendis Pharma AS. For market capitalisation and broader financial context, see ASND market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | $51.77 Million | $1.46 Billion | ▲ +114.8% |
| 2024 | -0.24x | $-306.20 Million | $1.29 Billion | ▲ +50.5% |
| 2023 | -0.48x | $-467.36 Million | $971.28 Million | ▲ +19.8% |
| 2022 | -0.60x | $-495.70 Million | $826.39 Million | ▲ +71.1% |
| 2021 | -2.07x | $-417.65 Million | $201.29 Million | ▼ -7.8% |
| 2020 | -1.92x | $-271.55 Million | $141.08 Million | ▲ +12.9% |
| 2019 | -2.21x | $-175.94 Million | $79.62 Million | ▲ +38.0% |
| 2018 | -3.57x | $-138.80 Million | $38.92 Million | ▲ +10.9% |
| 2017 | -4.00x | $-95.10 Million | $23.77 Million | ▲ +10.5% |
| 2016 | -4.47x | $-60.18 Million | $13.46 Million | ▼ -17.7% |
| 2015 | -3.80x | $-43.47 Million | $11.45 Million | ▼ -165.4% |
| 2014 | -1.43x | $-18.40 Million | $12.86 Million | ▼ -562.6% |
| 2013 | 0.31x | $6.31 Million | $20.40 Million | ▲ +1231.5% |
| 2012 | -0.03x | $-652.00K | $23.85 Million | — |